FDA granted Breakthrough Therapy designation to PKC412 (midostaurin), an investigational treatment for adults with newly-diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test, and who are eligible to receive standard induction and consolidation chemotherapy. The designation is primarily based upon results from the phase III RATIFY clinical trial. This study was conducted...
Up to 80% of adolescents and young adults with cancer are affected by reduced fertility after treatment—but only 50% received oncofertility counseling and preservation options prior to beginning treatment.
